Interim Final DEA Rule Places Serdexmethylphenidate in Schedule IV Following FDA Drug Approval
May 16, 2021 at 20:02:45 ET
The DEA has issued an interim final rule placing serdexmethylphenidate in Schedule IV of the Controlled Substances Act (CSA) (87 Fed. Reg. 24487, May 7, 2021).
The interim final rule on serdexmethylphenidate, including its salts, isomers and salts of isomers, followed the FDA’s March 2 approval of a new drug application from Commave Therapeutics S.A. in partnership with KemPharm In... Read More
